Clinical relevance of an objective - limit of detection - limit of quantification - based flow cytometry approach for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial

Autor:	Buccisano, F, Palmieri, R, Piciocchi, A, Arena, V, Maurillo, L, Del Principe, M, Paterno, G, Irno-Consalvo, M, Ottone, T, Divona, M, Conti, C, Fraboni, D, Lavorgna, S, Arcese, W, Voso, Mt, Venditti, A
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	measurable residual disease Acute myeloid leukemia immunophenotyping minimal residual disease Acute myeloid leukemia minimal residual disease measurable residual disease immunophenotyping Settore MED/15
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=od______3667::ca2daa861c1e77d4baa8aa41b454e339 https://hdl.handle.net/2108/293607 Zobrazit plný text záznamu